ChiCTR-IOR-15006942
尚未开始
/
/
/
2015-08-20
/
/
Degenerative osteoarthritis of the knee
比較膝關節内注射間充質幹細胞及透明質酸用於治療膝關節炎的效用
比較膝關節内注射間充質幹細胞及透明質酸用於治療膝關節炎的效用
比較膝關節内注射間充質幹細胞及透明質酸用於治療膝關節炎的效用
随机平行对照
其它
Randomized
/
The Chinese University of Hong Kong
/
30
/
1990-01-01
1990-01-01
/
Patients must comply with all the following criteria in order to be included in the study 1. Male and female subjects aged between 18 and < 65; 2. All patients must provide their written consent; 3. All patients must be affected by primary osteoarthritis of the knee (according to ACR - American College of Rheumatology - classification); In case a patient shows a bilateral OA, it will be included and treated for both knees; 4. All patients must have pain symptoms since at least 2 months; 5. All patients must experience, during the inclusion visit (T0), a pain level higher than or equal to 5.0 cm on a VAS scale of 10 cm; 6.All patients should have at least 8 years of school education; 7.Radiological evidence of osteoarthritis with Kellgren and Lawrence grade 2 and 3.;
请登录查看The presence of one or more of the following criteria will exclude the patient from the study: 1. Patients with previous cases of alcoholism or drug abuse; 2. Pregnancy and breast-feeding; 3. Presence of serious pathologies; 4. Hypersensitivity towards hyaluronic acid; 5. Intra-articular infiltrations of hyaluronic acid or steroids that are in the process of being administered or that have been interrupted since less than 3 months; 6. Steroid-based systemic therapy in progress or interrupted since less than 1 month and/or anti-clotting drugs; 7. History of fractures and/or severe traumas of the knee bone; 8. Significant hematologic diseases; 9. Non-consenting patients who have not provided the written Informed Consent; 10. Mechanical instability, ligamentous laxity/deficiency and gross deformity; 11. Isolated meniscal tear without evident of osteoarthritis.;
请登录查看Prof. Kevin HO Ki Wai
/
Prof. Kevin HO Ki Wai的其他临床试验
Department of Orthopaedics and Traumatology, The Chinese University of Hong Kong的其他临床试验
最新临床资讯
-
大鹏制药临床III期成功
新药说2026-08-13
-
新一代 EGFR-TKI 首个全球 III 期成功
丁香园 Insight 数据库2026-08-13
-
体外诊断原料网2026-08-13
-
佰傲谷BioValley2026-08-13
-
久有基金2026-08-13
-
重庆宸安生物2026-08-13
-
UmabsDB2026-08-13
-
希格生科2026-08-13
-
bioSeedin柏思荟2026-08-13
-
智飞智讯2026-08-13
全球药物研发中心
全球研发数据与行业前沿情报
-
2026-08-13
-
2026-08-13
-
2026-08-13
-
摩熵咨询 20 8
-
摩熵咨询 34 27
-
摩熵咨询 20 5
-
颁布机构:四川省经济和信息化厅、中共四川省委军民融合发展委员会办公室、四川省教育厅、四川省科学技术厅、四川省人力资源和社会保障厅、四川省卫生健康委员会、四川省医疗保障局、四川省中医药管理局、四川省药品监督管理局 2026-08-04
-
颁布机构:国家医保局 2026-07-31
-
颁布机构:国家药品审评中心(CDE) 2026-07-24
医药市场洞察中心
医药市场销售数据分析 · 智能洞察 · 竞争格局监测
-
医药市场销售数据分析 · 医院、实体药店、网上药店
-
市场竞争格局分析(靶点、药品类型、ATC大类)
-
2026-08-13
-
2026-08-13
-
2026-08-13
-
摩熵咨询 35 36
-
摩熵咨询 28 38
-
摩熵咨询 34 18
-
颁布机构:国家市场监督管理总局 2026-08-10
-
颁布机构:国家市场监督管理总局 2026-05-29
-
颁布机构:国家市场监督管理总局 2026-05-29
